Clinical Trials Register

Trials with a EudraCT protocol (44,380)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

44,380 result(s) found. Displaying page 1,782 of 2,219.

EudraCT Number: 2021-003478-30

Sponsor Protocol Number: CAAA802A12101

Start Date*: 2022-08-15

Sponsor Name:Novartis Pharma AG

Full Title: SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with heavily pre-treated PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) with or without...

Medical condition: PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10036908	Prostatic neoplasms malignant	HLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2021-000161-32	Sponsor Protocol Number: CLIN-52120-452	Start Date*: 2021-08-11
Sponsor Name:Ipsen Pharma
Full Title: A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with Onabotulinu...
Medical condition: upper limb spasticity (ULS) of any aetiology (in US and France) or post-stroke ULS (in Canada)
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2018-004124-10

Sponsor Protocol Number: 68284528MMY2003

Start Date*: 2020-08-07

Sponsor Name:Janssen-Cilag International NV

Full Title: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma

Medical condition: Multiple Myeloma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10028228	Multiple myeloma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2014-001578-32	Sponsor Protocol Number: 2012/49	Start Date*: 2014-11-10
Sponsor Name:CENTRE ANTOINE LACASSAGNE
Full Title: A phase I/II study of pazopanib in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and RT-CT (PAZOGLIO study)
Medical condition: Glioblastoma
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2017-002400-26

Sponsor Protocol Number: 64407564MMY1001

Start Date*: 2019-02-06

Sponsor Name:Janssen-Cilag International NV

Full Title: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Medical condition: Relapsed or Refractory Multiple Myeloma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10010331 - Congenital, familial and genetic disorders	10005330	Blood and lymphatic system disorders congenital	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2020-001685-11	Sponsor Protocol Number: ICO-2020-01	Start Date*: 2020-06-26
Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
Full Title: RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine
Medical condition: RElapse in previously irradiated Prostate bed
Disease:
Population Age: Adults		Gender: Male
Trial protocol: FR (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2019-003047-30

Sponsor Protocol Number: 209664

Start Date*: 2020-02-14

Sponsor Name:GlaxoSmithKline Research & Development Ltd

Full Title: A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone i...

Medical condition: Multiple Myeloma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	100000004864	10028228	Multiple myeloma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2018-000186-36

Sponsor Protocol Number: IB2017-04

Start Date*: 2019-01-07

Sponsor Name:Institut Bergonié

Full Title: Phase III trial investigating the potential benefit of intensified peri-operative Chemotherapy in patients with in high-risk CINSARC patients with resectable soft-tissue SARComas

Medical condition: Resectable, non-metastatic soft-tissue sarcoma (STS)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10039494	Sarcoma NOS	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2007-007616-28

Sponsor Protocol Number: RV-MM-PI-302

Start Date*: 2008-01-31

Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS

Full Title: A MULTICENTER, OPEN LABEL STUDY OF ORAL REVLIMID AND PREDNISONE (RP) FOLLOWED BY ORAL REVLIMID MELPHALAN AND PREDNISONE (MPR) IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS

Medical condition: NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10028229	Multiple myelomas	HLT

Population Age: Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2017-000087-15

Sponsor Protocol Number: BP39529

Start Date*: 2017-12-21

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015/PRASINEZUMAB (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE WITH A 6...

Medical condition: Parkinson’s disease

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029205 - Nervous system disorders	10061536	Parkinson's disease	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)

Trial results: View results

EudraCT Number: 2019-003610-13

Sponsor Protocol Number: MK-3475-03B

Start Date*: 2020-12-01

Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Full Title: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03B

Medical condition: Renal Cell Carcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10038409	Renal cell carcinoma NOS	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2009-011470-15

Sponsor Protocol Number: AC-058B202

Start Date*: 2010-03-30

Sponsor Name:ACTELION Pharmaceuticals Ltd

Full Title: Multicenter, randomized, double-blind, parallel-group extension to study AC 058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ponesimod, an oral S1P1 ...

Medical condition: relapsing-remitting multiple sclerosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029205 - Nervous system disorders	10063399	Relapsing-remitting multiple sclerosis	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: FI (Completed) SE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) BG (Completed) PL (Completed) HU (Completed) NL (Completed) AT (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2009-015844-41

Sponsor Protocol Number: BMN162-502

Start Date*: 2013-07-25

Sponsor Name:BioMarin International Ltd.

Full Title: A Phase IV Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children with Phenylketonuria Treated with Sapropterin Dihydrochloride (Kuvan®) for 7 Years.

Medical condition: Phenylketonuria

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	100000004850	10034873	Phenylketonuria (PKU)	LLT

Population Age: Children, Under 18

Gender: Male, Female

Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2009-018083-94

Sponsor Protocol Number: IEO S513/110

Start Date*: 2010-07-29

Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA

Full Title: Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppressio...

Medical condition: High risk Hematologic Malignancies

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10024324		HLGT
	9.1		10025323		HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2010-020337-99

Sponsor Protocol Number: WA21092

Start Date*: 2011-10-20

Sponsor Name:F.Hoffmann-La Roche

Full Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc...

Medical condition: Relapsing Multiple Sclerosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029205 - Nervous system disorders	10063399	Relapsing-remitting multiple sclerosis	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) LV (Completed) HU (Completed) FI (Completed) DE (Completed) BE (Completed) SK (Completed) AT (Completed) NL (Ongoing) LT (Completed) EE (Completed) PT (Completed) BG (Completed) ES (Ongoing) PL (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2010-020338-25

Sponsor Protocol Number: WA25046

Start Date*: 2010-11-02

Sponsor Name:F.Hoffmann-La Roche

Full Title: A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis

Medical condition: Primary Progressive Multiple Sclerosis (PPMS)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029205 - Nervous system disorders	10063401	Primary progressive multiple sclerosis	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: LT (Completed) ES (Ongoing) BE (Completed) FR (Completed) HU (Completed) NL (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PT (Completed) AT (Completed) FI (Completed) IT (Completed) GR (Completed) BG (Completed) DK (Prematurely Ended) PL (Completed)

Trial results: View results

EudraCT Number: 2010-020315-36

Sponsor Protocol Number: WA21093

Start Date*: 2011-10-18

Sponsor Name:F.Hoffmann-La Roche

Medical condition: Relapsing Multiple Sclerosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10029205 - Nervous system disorders	10063399	Relapsing-remitting multiple sclerosis	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: SK (Completed) BE (Completed) SE (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) BG (Completed) FR (Completed) IE (Completed) IT (Completed) CZ (Completed)

Trial results: View results

EudraCT Number: 2010-018873-39

Sponsor Protocol Number: 26866138MMY2069

Start Date*: 2010-07-30

Sponsor Name:Dutch-Belgian Cooperative Trial Group for Hematology Oncology

Full Title: A multicenter phase II study of subcutaneous Velcade plus oral Melphalna and Prednisone or plus Oral cyclophosphamide and Prednisone or plus Prednisone in newly diagnosed elderly multiple myeloma p...

Medical condition: Newly diagnosed elderly multiple myeloma patients

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10028228		LLT

Population Age: Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2010-021111-17

Sponsor Protocol Number: IST-CAR-506

Start Date*: 2011-05-16

Sponsor Name:HOVON Foundation

Full Title: A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

Medical condition: newly diagnosed multiple myeloma patients

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	13.1	10005329 - Blood and lymphatic system disorders	10028229	Multiple myelomas	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2021-005605-27

Sponsor Protocol Number: TNG908-C101

Start Date*: 2022-09-07

Sponsor Name:Tango Therapeutics, Inc.

Full Title: A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors

Medical condition: Phase 1: • Locally advanced or metastatic MTAP-deleted solid tumors (with the exception of gliomas) Phase 2: • Arm 1: Locally advanced or metastatic MTAP-deleted squamous and nonsquamous NSCLC ...

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004864	10065252	Solid tumor	LLT
	20.0	100000004864	10079440	Non-squamous non-small cell lung cancer	LLT
	24.0	100000004864	10085300	Squamous non-small cell lung cancer	LLT
	21.0	100000004864	10027408	Mesothelioma malignant advanced	LLT
	21.0	100000004864	10027409	Mesothelioma malignant localised	LLT
	21.1	100000004864	10026667	Malignant peripheral nerve sheath tumor	LLT
	20.0	100000004864	10008594	Cholangiocarcinoma non-resectable	LLT
	21.1	100000004864	10077846	Cholangiocarcinoma metastatic	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials